Page last updated: 2024-11-04

salmeterol xinafoate and Idiopathic Parkinson Disease

salmeterol xinafoate has been researched along with Idiopathic Parkinson Disease in 1 studies

salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Weichert, D1
Stanek, M1
Hübner, H1
Gmeiner, P1

Other Studies

1 other study available for salmeterol xinafoate and Idiopathic Parkinson Disease

ArticleYear
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
    Bioorganic & medicinal chemistry, 2016, 06-15, Volume: 24, Issue:12

    Topics: Adrenergic beta-2 Receptor Agonists; Animals; Benzoxazines; CHO Cells; Cricetulus; Dopamine Agonists

2016